If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The Malaysian Armed Forces has three branches: the Malaysian Army, Royal Malaysian Navy and the Royal Malaysian Air Force. There is no conscription, and the required age for voluntary military service is 18. The military uses 1.5% of the country's GDP, and employs 1.23% of Malaysia's manpower. Malaysian peacekeeping forces of MALBATT have contributed to many U.N. peacekeeping missions, such as in Congo, Iran–Iraq, Namibia, Cambodia, Bosnia and Herzegovina, Somalia, Kosovo, East Timor, and Lebanon. The Five Power Defence Arrangements is a regional security initiative that has been in place for almost 40 years. It involves joint military exercises held among Malaysia, Singapore, Australia, New Zealand, and the United Kingdom. Joint exercises and war games have also been held with Brunei, China, India, Indonesia, Japan, and the United States. Malaysia, Philippines, Thailand, and Vietnam have agreed to host joint security force exercises to secure their maritime border and tackle issues such as illegal immigration, piracy, and smuggling. Previously there were fears that extremist militant activities in the Muslim areas of the southern Philippines and southern Thailand would spill over into Malaysia. Because of this, Malaysia began to increase its border security.
In early medieval Europe, some accounts stated that Common Vervain was used to staunch Jesus' wounds after his removal from the cross; hence names like "Holy Herb" or (e.g. in Wales) "Devil's bane". Because of the association with the Passion of Christ, it came to be used in ointments to drive out and repel "demonic" illnesses. Vervain flowers are engraved on cimaruta, Italian anti-stregheria charms. In the 1870 The History and Practice of Magic by "Paul Christian" (Jean-Baptiste Pitois) it is employed in the preparation of a mandragora charm. A Royal Navy Arabis-class sloop of the World War I era was named HMS Verbena, and in World War II a Group 1 Flower-class corvette bore the same name; a Group 2 vessel of the latter class was called HMS Vervain. The only Verbena widely found in England in a wild state is common vervain, though it is just as possible that the names reference the popular ornamental verbenas, such as the garden vervain.
=== Aerobic activity === A six-week training program in 1998 that included 30 minutes of aerobic activity three times per week set at 60% maximum heart rate (predicted by age) resulted in increased VO2 max (i.e. maximal oxygen consumption or aerobic capacity), diminished pain, reduced muscle impairment, and improved quality of life.
West married fellow scholar Stephanie Pickard in 1960 at Nottingham, after meeting her at a lecture given by Eduard Fraenkel at Corpus Christi College, Oxford, whose seminars he attended. He became a junior research fellow at St John's College from 1960 to 1963. His doctoral thesis, a commentary on Hesiod's Theogony, won the Conington Prize for the best classical dissertation of the year in 1965, and was edited as a printed book the following year. From the mid-sixties, West took especial interest in the relation of Greek literature to the Orient, and over several decades, culminating in his masterpiece The East Face of Helicon (1997), defended his view that Greek literature derives significant influences and inspiration from Near Eastern literature. He took up a position as tutorial fellow at University College, a position he filled from 1963 to 1974. In 1973 he became the second youngest person to be elected a Fellow of the British Academy, at the age of 35. He obtained a chair at Royal Holloway and Bedford New College, which he held from 1974 until 1991, when he became a fellow of All Souls College. West retired formally in 2004, but remained active in All Souls until the end of his life.
== Uses == L-citrulline is sold as a dietary supplement. It may be used in commercial products as a topical moisturizing agent for skin or for hairstyling. Although promoted to support athletic performance, there is no good evidence that taking citrulline as a supplement is effective or safe for this purpose. Citrulline has not been approved as a prescription drug, has no confirmed clinical uses, and remains under preliminary research, as of 2026.
Sources: en.wikipedia.org
=== Messenger RNA (mRNA) carries genetic information that directs protein synthesis === The concept of messenger RNA emerged during the late 1950s, and is associated with Crick's description of his "central dogma of molecular biology", which asserted that DNA led to the formation of RNA, which in turn led to the synthesis of proteins. During the early 1960s, sophisticated genetic analysis of mutations in the lac operon of E. coli and in the rII locus of bacteriophage T4 were instrumental in defining the nature of both messenger RNA and the genetic code. The short-lived nature of bacterial RNAs, together with the highly complex nature of the cellular mRNA population, made the biochemical isolation of mRNA very challenging. This problem was overcome in the 1960s by the use of reticulocytes in vertebrates, which produce large quantities of mRNA that are highly enriched in RNA encoding alpha- and beta-globin (the two major protein chains of hemoglobin). The first direct experimental evidence for the existence of mRNA was provided by such a hemoglobin synthesizing system.
Andrew Krepinevich argued that an "archipelagic defense" of the countries that make up the first island chain would make up a big part of the implementation of the national defense strategy of 2018. A 2019 report by the Center for Strategic and Budgetary Assessments "proposes a U.S. military strategy of Maritime Pressure and a supporting joint operational concept, “Inside-Out” Defense, to stabilize the military balance in the Western Pacific and deny China the prospect of a successful fait accompli." The first island chain plays a central role in the report. In 2020, the United States Marine Corps started shifting its tactics in conjunction with the United States Navy to be deployed along or near the first island chain. In 2021, the United States Marine Corps announced a goal of three additional Pacific-based regiments. The 2025 National Security Strategy noted the need "to deter adversaries and protect the First Island Chain."
=== Charles W. Post === The second major innovator in the cereal industry was Charles W. Post, a salesman who was admitted to Kellogg's sanitarium as a patient in the late 1800s. While there, he grew deeply impressed with their all-grain diet. Upon his release, he began experimenting with grain products, beginning with an all-grain coffee substitute called Postum. In 1897 (or 1898) he introduced Grape-nuts, the concentrated cereal with a nutty flavor (containing neither grapes nor nuts). Good business sense, determination, and powerful advertising produced a multimillion-dollar fortune for Post in a few years. After his death, his company acquired the Jell-O company in 1925, Baker's Chocolate in 1927, Maxwell House coffee in 1928, and Birdseye frozen foods in 1929. In 1929, the company changed its name to General Foods. In 1985, Philip Morris Tobacco Company bought General Foods for $5.6 billion (equivalent to $16.8 billion today) and merged it with its Kraft division. Because of Kellogg and Post, the city of Battle Creek, Michigan, is nicknamed the "Cereal Capital of the World".
Stable isotope labeling involves the use of non-radioactive isotopes that can act as tracers used to model several chemical and biochemical systems. The chosen isotope can act as a label on that compound that can be identified through nuclear magnetic resonance (NMR) and mass spectrometry (MS). Some of the most common stable isotopes are 2H, 13C, 15N, and 18O, which can further be produced into NMR solvents, amino acids, nucleic acids, lipids, common metabolites and cell growth media. The compounds produced using stable isotopes are either specified by the percentage of labeled isotopes (that is, 30% uniformly labeled 13C glucose contains a mixture that is 30% labeled with 13C isotope and 70% naturally labeled carbon) or by the specifically labeled carbon positions on the compound (that is, 1-13C glucose which is labeled at the first carbon position of glucose). A network of reactions adopted from the glycolysis pathway and the pentose phosphate pathway is shown in which the labeled carbon isotope rearranges to different carbon positions throughout the network of reactions. The network starts with fructose 6-phosphate (F6P), which has six carbon atoms with a label 13C at carbon positions 1 and 2. 1,2-13C F6P becomes two glyceraldehyde 3-phosphate (G3P), one 2,3-13C T3P and one unlabeled T3P. The 2,3-13C T3P can now be reacted with sedoheptulose 7-phosphate (S7P) to form an unlabeled erythrose 4-phosphate(E4P) and a 5,6-13C F6P. The unlabeled T3P will react with the S7P to synthesize unlabeled products.
Sources: en.wikipedia.org
Seaborg was notified and the team left to sleep. Additional analysis and further experimentation showed the produced mendelevium isotope to have the expected mass of 256 and decay by electron capture to fermium-256 (half-life 157.6 minutes), the source of the observed fission.
Dennis Richard Abercrombie Matheson. Chair, Tenant Farmers Association Cymru. For services to the Tenanted Agricultural Sector in Wales. Zamanganga Mbatha. Head of Profound and Multiple Learning Disabilities, Royal Docks Academy. For services to Teenagers with Learning Difficulties in the London Borough of Newham. Hugh McAninch. Lately Regional Coordinator, The Compassionate Friends. For services to Bereaved Families in Scotland. Elizabeth McCrory. Regional Lead, UK Export Finance. For services to Exporting Businesses in Northern Ireland. Gordon Stirling McIntyre. Founder and Chair, Hospitality Health. For services to the Tourism and Hospitality Industry in Scotland. Gwyneth Kathleen McKenzie. Team District Commissioner, Hadrian District, Scout Association. For services to Young People and to the community in Northumberland, North Tyneside and Newcastle upon Tyne. James Ian McLean. Deputy Chief Nurse, Programme Delivery, Health Education England. For services to Nursing. Robert William McVeigh. For services to the Commonwealth Games in Northern Ireland. Donna Elaine McWilliams. Deputy Group Co-ordinator, Stepping Stones Play and Learn. For services to Early Years and Special Needs Education. Marion Anne Meakin. Senior Probation Officer, North West Probation Service, HM Prison and Probation Service. For services to Reducing Reoffending and Public Protection. Christiana Melam, Chief Executive, National Association of Link Workers. For services to Social Prescribing. Mohammed Gulam Moula Miah. Chairman, Rajnagar Business Group and Moula Foundation.
Exothermic chemical reactions in closed systems do not change mass, but do become less massive once the heat of reaction is removed, though this mass change is too small to measure with standard equipment. In nuclear reactions, the fraction of mass that may be removed as light or heat, i.e. binding energy, is often a much larger fraction of the system mass. It may thus be measured directly as a mass difference between rest masses of reactants and (cooled) products. This is because nuclear forces are comparatively stronger than the Coulombic forces associated with the interactions between electrons and protons that generate heat in chemistry.
BRD-6929, also widely known as "compound 60" (Cpd-60 or Cmpd60), is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It has been described in the past as the prototypical selective HDAC1 and HDAC2 inhibitor. However, subsequent findings suggest that BRD-6929 may not actually be selective for HDAC1 and HDAC2 over HDAC3.
== Risk factors == The mechanism of injury for NAION used to be quite controversial. However, experts in the field have come to a consensus that most cases involve two main risk factors. The first is a predisposition in the form of a type of optic disc shape. The optic disc is where the axons from the retinal ganglion cells collect into the optic nerve. The optic nerve is the bundle of axons that carry the visual signals from the eye to the brain. This optic nerve must penetrate through the wall of the eye, and the hole to accommodate this is usually 20-30% larger than the nerve diameter. In some patients the optic nerve is nearly as large as the opening in the back of the eye, and the optic disc appears "crowded" when seen by ophthalmoscopy. A crowded disc is also referred to as a "disc at risk". While a risk factor, the vast majority of individuals with crowded discs do not experience NAION. The second major risk factor involves more general cardiovascular risk factors. The most common are diabetes, hypertension and high cholesterol levels. While these factors predispose a patient to develop NAION, the most common precipitating factor is marked fall of blood pressure during sleep (nocturnal arterial hypotension)- that is why at least 75% of the patients first discover visual loss first on waking from sleep. When other risk factors for NAION are present, taking blood pressure medications at night should be avoided as this can exacerbate nighttime hypotension. Beta blockers in particular are associated with increased incidence of NAION.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.